Alessandro Mazzocca

Dr. Alessandro Mazzocca

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2024 in ESMO Open
Verified
Journal Article
Open access
BVB. Vincenzi
B. Vincenzi
POPier Paolo Olimpieri
Pier Paolo Olimpieri
SCS. Celant
S. Celant
AMAlessandro Mazzocca
Alessandro Mazzocca
ACA. Cortellini
A. Cortellini
PCP.G. Casali
P.G. Casali
Pazopanib is part of the therapeutic armamentarium for the treatment of patients with advanced non-adipocytic soft tissue sarcomas (STS) who have received prior chemotherapy, but its optimal use in STS histologies is still left to be further defined. Data on STS patients treated with pazopanib in Italy have been prospectively collected from July 2013 to December 2019 through a drug monitoring registry managed by the Italian Medicines Agency (AIFA). This nationwide observational cohort study included patients with advanced STS who received pazopanib. Clinicians were mandatorily requested to fill in the AIFA monitoring registry in order to prescribe pazopanib. Patients were recorded on the basis of their clinical characteristics, histological subtype captured at the time of treatment start, and clinical outcome. Primary outcome was time to treatment discontinuation (TTD). Secondary outcomes recorded were frequency of dose reduction and time to first dose reduction. We analyzed data from 1964 sarcoma patients. The most represented histological subtypes were leiomyosarcoma (44.7%), undifferentiated sarcomas/not otherwise specified (11.5%), and synovial sarcoma (8.1%). Overall, the median TTD was 106 days. The variables significantly associated to shorter TTD were Eastern Cooperative Oncology Group performance status (1-2 versus 0), the number of previous lines of treatment (2-4 versus 0-1) and prescribed dose (200 mg or 400 mg versus 800 mg, all once daily). Among the most represented (>20 patients) histological subtypes, we also observed longer TTD in patients with histological diagnosis of malignant solitary fibrous tumor if compared with undifferentiated sarcoma not otherwise specified. In this nationwide observational real-world study, the outcomes are similar to those reported in the pivotal trial (PALETTE study). Our study includes a significant number of patients with rare/ultra-rare sarcoma subtypes and underlines possible differences in treatment duration among these histologies.

17 March 2025 in Histopathology
Verified
Journal Article
Closed access
ANAzfar Neyaz
Azfar Neyaz
SCSimon Chiosea
Simon Chiosea
IGIsabella Giovannoni
Isabella Giovannoni
AMAlessandro Mazzocca
Alessandro Mazzocca
LLLucas da Gama Lobo
Lucas da Gama Lobo
IJIvy John
Ivy John

9 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AMAlessandro Mazzocca
Alessandro Mazzocca
FPFlavia Paternostro
Flavia Paternostro
SGSerena Garofalo
Serena Garofalo
MSMarianna Silletta
Marianna Silletta
DRDavide Romandini
Davide Romandini
BVBruno Vincenzi
Bruno Vincenzi
(1) Background: Quality of life (QoL) assessment is a crucial aspect for patients diagnosed with cancer. Over the years, different tools have been developed to measure QoL, both generic and pathology specific, but the inclusion of quality of life among other indicators of efficacy in randomized controlled trials (RCTs) remains a controversial issue. In this review, we aim to review the frequency and modality of QoL assessment in RCTs, enrolling patients diagnosed with mesenchymal tumors. (2) Methods: An electronic literature search of bone and soft tissue sarcoma and GIST-related RCTs published between January 2000 and December 2023 was performed by two independent reviewers using PubMed. English-language phase II and III clinical trials enrolling at least more than 15 patients were included, regardless of the disease stage. Studies involving patients under the age of 18 years or for which the full text was not available were excluded. For each study, data regarding the journal and year of publication, the study design, the primary objective, and the evaluation of quality of life as an endpoint with any type of patient-reported outcomes used were extracted. (3) Results: Among the 742 publications screened, 171 resulted eligible. QoL assessment was listed among the endpoints in 35 trials and QoL results were reported in 29 primary publications. In these trials, 16 included patients with soft tissue sarcomas, 8 Kaposi sarcomas, 6 GIST, and 3 desmoid tumors. Among all the trials included, 10.4% on an adjuvant/neoadjuvant setting and 24.4% on a metastatic setting included QoL as an endpoint. The proportion of trials, including QoL, was variable over time, as follows: 16.9% of trials in 2000–2014 vs. 23.4% in 2015–2023. In 35 trials, including QoL endpoints, 27 had a superiority design and 25 reported a positive result. In the majority of trials (80%), the tools for QoL assessment were generic and those mostly used were the EORTC QLQ-C30, the EQ-5D questionnaire, and the modified Brief Pain Inventory–Short Form. (4) Conclusions: Quality of life has not been assessed or published in many phase II and III trials, despite an improvement over time. QoL evaluation in RCTs should be considered even more carefully in patients with rare tumors, where the low number of patients who can be enrolled makes it difficult to draw statistically significant conclusions on the effectiveness of treatments.

8 March 2026 in European Journal of Cancer
Verified
Journal Article
Open access
GBGiacomo G. Baldi
Giacomo G. Baldi
CGClaudia Giani
Claudia Giani
SLSilva Ljevar
Silva Ljevar
RDRyan A Denu
Ryan A Denu
ANAndrea Napolitano
Andrea Napolitano
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
To report the outcomes in adult patients with advanced pleomorphic rhabdomyosarcoma (P-RMS) treated with systemic therapy. This global, multicenter, retrospective study conducted within the Pushing Ultra-Rare Sarcomas Towards Hope consortium (PUSH) included patients > 40 years with histologically confirmed advanced P-RMS, treated with at least one line of systemic therapy between 2013 and 2023. The primary endpoint was progression-free survival from first diagnosis of advanced disease, and from systemic treatment start (PFS-1 and PFS-2). Secondary endpoints included overall response rate (ORR), overall survival from first diagnosis of advanced disease and from treatment start (OS-1 and OS-2), and treatment-specific outcomes. Seventy-seven patients were included from 21 sarcoma reference centers. At a median follow-up of 44 months (IQR: 17.0-74.8), 49 (64%) patients had died and 48 (62%) had progressed. The median OS-1 and PFS-1 were 13.6 (95% confidence interval (CI): 9.4-22.5) and 5.4 (95% CI: 4.2-7.3) months, respectively. Two- and three-year OS-1 were 32.5% and 30.3%. Anthracycline-based regimens (n = 42) achieved a 50% ORR, with mPFS-2 and mOS-2 of 5.2 and 19.2 months; gemcitabine-based regimens (n = 15) a 42% ORR, with mPFS-2 and mOS-2 of 3.7 and 7.8 months; pazopanib (n = 6) a 33% ORR, with mPFS-2 and mOS-2 of 2.4 and 4.2 months; PD-1 inhibitors (n = 2) induced one response lasting 53 months. This series of advanced P-RMS treated with systemic agents, the largest available to date, showed meaningful activity of anthracycline- and gemcitabine-based regimens, and anecdotal responses to pazopanib and PD-1 inhibitors. Further prospective validation is planned.

20 January 2026 in ESMO Open
Verified
Journal Article
Open access
CGC. Giani
C. Giani
GBGiacomo Giulio Baldi
Giacomo Giulio Baldi
SLS. Ljevar
S. Ljevar
RDRyan A Denu
Ryan A Denu
VAV. Andelkovic
V. Andelkovic
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
The purpose of this study was to report the outcome of primary localized pleomorphic rhabdomyosarcoma (P-RMS). Patients with primary localized P-RMS, aged >40 years, and surgically treated with curative intent from January 2013 to December 2023 were enrolled from 25 institutions across 12 countries. Pathological inclusion criteria were predefined by expert pathologists per established World Health Organization guidelines. Primary endpoint was overall survival (OS). Secondary endpoints were disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR), CCI of distant metastases (DM), post-relapse OS, and post-metastasis OS. A total of 93 patients were eligible and included in the present study. At a median follow-up of 39.8 months (interquartile range 22.83-85.69 months), 32/93 (34%) patients died and 53/93 (57%) recurred. The corresponding 5-year OS and DFS were 57.7% [95% confidence interval (CI) 46.7% to 71.2%] and 35.8% (95% CI 26.3% to 48.9%), respectively. Younger age, R0 surgical margins, and administration of radiotherapy were positive prognostic factors in multivariable analysis for DFS. LR and DM were developed in 14/93 (15%) and 39/93 (42%) patients, respectively. The corresponding 3-year CCI-LR and DM were 16% (95% CI 8.9% to 25%) and 44% (95% CI 33% to 55%). Post-metastasis median OS was 14.3 months (95% CI 9.4 months-not reached). While P-RMS is known to be an aggressive histologic sarcoma subtype, one-third of patients with primary localized disease may be cured. The contribution of chemotherapy and radiotherapy to the cure rate remains unclear. Post-metastatic outcomes mirror those observed in other sarcomas.

18 January 2024 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
BVBruno Vincenzi
Bruno Vincenzi
ACAlessio Cortellini
Alessio Cortellini
AMAlessandro Mazzocca
Alessandro Mazzocca
SOSarah Orlando
Sarah Orlando
DRDavide Romandini
Davide Romandini
DPDavid J. Pinato
David J. Pinato
Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific population. Methods: We described COVID-19 morbidity and mortality among patients with STS across ‘Omicron’ (15 December 2021–31 January 2022), ‘Pre-vaccination’ (27 February 2020–30 November 2020), and ‘Alpha-Delta’ phase (01 December 2020–14 December 2021) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR28) and COVID-19 severity were also described according to the SARS-CoV-2 vaccination status, while the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders. Results: Out of 3820 patients, 97 patients with STS were included. The median age at COVID-19 diagnosis was 56 years (range: 18–92), with 65 patients (67%) aged < 65 years and most patients had a low comorbidity burden (65, 67.0%). The most frequent primary tumor sites were the abdomen (56.7%) and the gynecological tract (12.4%). In total, 36 (37.1%) patients were on cytotoxic chemotherapy within 4 weeks prior to COVID-19. The overall CFR28 was 25.8%, with 38% oxygen therapy requirement, 34% rate of complications, and 32.3% of hospitalizations due to COVID-19. CFR28 (29.5%, 21.4%, and 12.5%) and all indicators of COVID-19 severity demonstrated a trend toward a numerical improvement across the pandemic phases. Similarly, vaccinated patients demonstrated numerically improved CFR28 (16.7% versus 27.7%) and COVID-19 morbidity compared with unvaccinated patients. Patients who were on chemotherapy experienced comparable CFR28 (19.4% versus 26.0%, p = 0.4803), hospitalizations (50.0% versus 44.4%, p = 0.6883), complication rates (30.6% versus 34.0%, p = 0.7381), and oxygen therapy requirement (28.1% versus 40.0%, p = 0.2755) compared to those who were not on anticancer therapy at COVID-19, findings further confirmed by the IPTW-fitted multivariable analysis. Conclusion: In this study, we demonstrate an improvement in COVID-19 outcomes in patients with STS over time. Recent exposure to chemotherapy does not impact COVID-19 morbidity and mortality and SARS-CoV-2 vaccination confers protection against adverse outcomes from COVID-19 in this patient population.